DUBLIN – Sisaf Ltd. has exercised an option on an Italian preclinical program to treat a rare bone disorder, autosomal dominant osteopetrosis type 2, with an siRNA molecule, which it will deliver with its in-house Bio-courier technology.
The skeleton undergoes continuous remodeling throughout life in response to diverse environmental stimuli. Osteoclasts, which are specialized cells on the bone surface, break down old bone tissue (in a process known as bone resorption) and build it back up. Dysregulation of osteoclast formation and function can lead to bone fragility, including osteoporosis, which is estimated to affect over 10 million people globally.